The clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of lung cancer-related entities require individualized development, typically including multidimensional management, such as drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions, adapted to the timely schedule of disease changes. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of lung cancer-associated entities. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.